Adam Gulhan, MD
Neurology · Marinette, WINPI 1841294345
Payments from drug & device makers
Across 63 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$336
- Novartis$258
- AbbVie$218
- UCB, Inc.$98
- Biogen$48
- Sanofi$47
- plus $196 from 9 others
What the payments were for
- Food & beverage$94879%
- Education$25321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $336 |
| Novartis | 18 | $258 |
| AbbVie(2 entities) | 15 | $218 |
| UCB, Inc. | 4 | $98 |
| Biogen | 3 | $48 |
| Sanofi | 3 | $47 |
| Bristol Myers Squibb | 2 | $29 |
| Genentech USA, Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 2 | $26 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
How this compares
$1,201 in reported general payments places this provider in the 60th percentile of 308 neurology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 24 | $18,586 |
| Emgality PenGalcanezumab-Gnlm | 14 | $8,901 |
| Levetiracetam | 96 | $3,223 |
| Lacosamide | 26 | $2,407 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 54 | $1,568 |
| Gabapentin | 85 | $1,318 |
| Memantine Hcl | 57 | $1,063 |
| Acetazolamide | 12 | $1,058 |
| Memantine Hcl ErMemantine Hcl | 16 | $888 |
| RizatriptanRizatriptan Benzoate | 29 | $755 |
| Donepezil Hcl | 81 | $752 |
| Primidone | 27 | $665 |
| Baclofen | 32 | $664 |
| Nortriptyline Hcl | 42 | $422 |
| Topiramate | 70 | $393 |
Paid to pharmacies, not to this prescriber.
Other neurology in Marinette
- Bhupendra KhatriMilwaukee$7.3M
- Ahmed ObeidatMilwaukee$6M
- James NapierGreen Bay$1.7M
- Malgorzata FranczakMilwaukee$1.7M
- Staley BrodMilwaukee$1.3M
- Daniel LongNeenah$1.2M
- Ankush BhatiaMadison$983K
- Sam HooshmandMilwaukee$783K
- Aaron BubolzGreen Bay$595K
- Christopher LuzzioMadison$555K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.